3 results
Approved WMOWill not start
To evaluate the safety, tolerability and efficacy of IZD334 to reduce CRP in cardiovascular high-risk patients.
Approved WMORecruiting
Primary Objective1. To evaluate the efficacy of IMU-838 versus placebo as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy in progressive multiple sclerosis (PMS) patients with the Structural Image…
Approved WMOCompleted
Primary:To demonstrate the non-inferior antiviral activity of CAB LA + RPV LA every two months compared to a BIK single tablet regimen administered once daily over 12 months in suppressed HIV-1 infected antiretroviral therapy (ART)-experienced…